Is under-eye filler safe, and what can go wrong?

Why the under-eye area is treated with extra care

The hollow under the eye, often called the tear trough, sits where the thin skin of the lower eyelid meets the cheek. The skin here is among the thinnest on the face, the muscle that closes the eye (the orbicularis oculi) lies directly beneath it, and the area drains fluid less readily than the rest of the face. Small amounts of filler show. Too much, or filler placed too shallow, shows more.

That is why this area is usually described as advanced work. A review of under-eye treatment in Aesthetic Surgery Journal Open Forum describes the general approach the literature favors: filler placed deep, close to the bone of the orbital rim, in small amounts, often over more than one visit, with a deliberate aim of under-correcting. The same review notes that the hollow is often part of wider volume loss in the midface, and that supporting the cheek first can reduce how much product is needed under the eye.

Which fillers are FDA-approved for under the eyes

Each filler is approved for specific areas, and only two hyaluronic acid fillers carry an approval for this one.

• Restylane Eyelight. the FDA approved Restylane Eyelight on May 8, 2023 for improving the appearance of hollow areas under the eyes in people 21 years of age and older ^{(source, verified Nov 2026)}.
• Juvéderm Volbella XC. an FDA approval dated May 28, 2021 expanded the use of Juvéderm Volbella XC to the infraorbital hollow for adults over age 21 ^{(source, verified Nov 2026)}.

Other fillers used under the eye are being used off-label. That is legal when a prescriber judges it appropriate, but it means the product was not studied and approved for this area. The FDA’s broader guidance shows why the distinction matters: the FDA's general dermal filler page lists injecting the periorbital area, around the eyes, among the uses it recommends against and says those uses are not approved, adding that the risks of unapproved uses are not known ^{(source, verified Nov 2026)}. The specific approvals above are narrower exceptions to that caution, for named products, in named patients. The FDA’s own advice to patients is to ask for the product’s patient labeling, which shows which areas it is approved for.

What the approval study measured

The Restylane Eyelight study is the most detailed public record of what happens when hyaluronic acid filler is placed under the eye under controlled conditions.

The study also shows who was left out. Its exclusion criteria included a history of recurrent or chronic swelling under the eyes, rosacea, uncontrolled severe seasonal allergies, a lower lid that sits low or eyes that bulge, festoons, large or herniating fat pads under the eyes, and dark circles caused by pigment rather than by a hollow’s shadow. Results in people outside those limits were not measured.

What can go wrong

Swelling and bruising in the first week

These are expected. in 28-day diaries after the first treatment, participants most often recorded tenderness (89.7 percent) and swelling (85.0 percent), followed by bruising (63.1 percent), redness (61.5 percent), pain (59.8 percent) and lumps or bumps (53.5 percent), and these were generally tolerable and lasted 7 days or less ^{(source, verified Nov 2026)}. Under the eye, even ordinary swelling is easy to see because the skin is thin.

Malar edema: puffiness that lingers or returns

Malar edema is swelling of the upper cheek and lower lid that persists or appears later. Hyaluronic acid draws water, and the under-eye area clears fluid slowly, so excess product here can show as a puffy bag or a swollen band along the top of the cheek. The Aesthetic Surgery Journal Open Forum review notes that late-onset edema can develop weeks, months or even years after treatment, and that people with a history of fluid retention or eyelid swelling are poorer candidates. The FDA safety summary adds that late-onset events more than 2 years after injection, such as delayed inflammation or granulomas in the under-eye region, have been reported in low numbers after Restylane fillers ^{(source, verified Nov 2026)}.

The Tyndall effect

Filler placed too close to the surface under thin skin can scatter light and give the area a blue-gray tint. It is a placement problem, not an allergy. In long-term follow-up the figure is not small: in a retrospective review of 147 patients followed for at least 5 years after under-eye hyaluronic acid filler, masked reviewers found malar edema in 11 percent, blue-gray discoloration in 31.3 percent and contour irregularities in 30.5 percent, and about 90 percent of these were mild and needed no treatment ^{(source, verified Nov 2026)}.

Lumps, overcorrection and migration

Lumps and an over-full ridge are described in the reviews as a result of too much product or product placed too shallow. Muscle movement around the eye can also move filler from where it was placed, which a review in Diagnostics lists among the delayed effects of filler. Overcorrection is easier to avoid than to fix, which is why a staged plan with small amounts is the usual advice.

Vascular events and vision

Arteries run around the eye and connect with the vessels that supply it. The Restylane Eyelight safety summary lists blurred vision and blindness among the events reported to the manufacturer after treatment, and names the periorbital area, together with the nose and glabella, as a site where vascular occlusion with vision loss has been reported after facial filler. The best-known review of published cases puts it differently: a 2021 review of published vision-loss cases found no reports linked to tear trough injections, while noting that theoretical connections exist between the infraorbital artery and the arteries above the eye ^{(source, verified Nov 2026)}. Both can be true. Vision loss after under-eye filler appears to be rare in the published record, and the anatomy means it is not impossible.

Anatomy also varies. In the Aesthetic Surgery Journal Open Forum review, a laterally shifted course of the angular artery, which brings it closer to the under-eye area, has been observed in about 30 percent of Asian people ^{(source, verified Nov 2026)}. That review was funded by the maker of Juvéderm Volbella XC, which is worth knowing when reading its product-specific findings. The warning signs of a blocked artery, and how it is treated, are set out in what a vascular occlusion is and how it is treated.

Needle or cannula

A cannula is often recommended under the eye to reduce bruising and vascular risk. The approval study is a reminder that neither instrument is free of side effects: 12.7 percent of treated participants had an adverse event judged related to the product or the injection, all mild or moderate; the rate was 4.9 percent among those injected by needle and 20.9 percent among those injected by cannula ^{(source, verified Nov 2026)}.

Who is not a good candidate

Filler adds volume. It does not tighten loose skin, remove fat bags or change pigment. Drawing on the FDA study exclusions and the published reviews, the people least likely to be helped, or most likely to have problems, include those with:

• Prominent fat bags under the eyes or loose, crepey lower lid skin, where surgery may be the better first conversation.
• A history of puffiness, fluid retention, festoons or malar swelling.
• Very thin or translucent skin, where even well-placed filler can show.
• Dark circles caused by pigment or visible veins rather than a hollow.
• Filler already in the area that has not been accounted for.
• Active infection or inflammation near the eye, a bleeding disorder, severe allergies or a history of anaphylaxis, pregnancy or breastfeeding, which the FDA lists as reasons to delay treatment or as situations where safety is unknown.

What dissolving with hyaluronidase can and cannot do

Hyaluronidase is an enzyme that breaks down hyaluronic acid. It is the reason hyaluronic acid filler is the usual choice under the eye: if the result is lumpy, puffy, blue-tinged or simply too much, it can usually be dissolved. The reviews describe it as the first treatment for Tyndall discoloration, overcorrection, non-inflammatory lumps and persistent filler-related swelling.

It has limits. using hyaluronidase to dissolve cross-linked hyaluronic acid filler is an off-label use in the United States ^{(source, verified Nov 2026)}. hyaluronidase also breaks down the body's own hyaluronic acid, which the body restores within 15 to 20 hours ^{(source, verified Nov 2026)}. Dissolving can take more than one session, and the guideline advises the guideline recommends waiting a minimum of two weeks, until swelling has settled, before filler is placed again in a dissolved area ^{(source, verified Nov 2026)}. It does not act on fillers made of other materials, it does not treat pigment, and in the most serious complication its role is narrow: no proven treatment has been shown to reverse vision loss from filler, and case reports and animal models have not shown hyaluronidase restoring sight ^{(source, verified Nov 2026)}. That is why prevention, not reversal, carries the weight under the eye.

What a candid consultation covers

In Arizona, Tanya practices as a registered nurse under a delegating prescriber, and every new patient has a Good Faith Exam before any treatment. No one should be promised under-eye filler, or a particular result, before that exam. A consultation about this area should cover:

• Whether the concern is a hollow, a fat bag, loose skin or pigment, looked at in different lights and with the head in different positions.
• Any previous filler, surgery or treatment around the eyes, and any history of swelling or allergies.
• Whether the cheek, rather than the under-eye area, is the better place to start.
• Which product is proposed, whether it is approved for this area or used off-label, and why.
• The realistic range of results, the expected swelling, and the less common problems above.
• What happens if the result is not right, including dissolving, and what to do and whom to call if a warning sign appears after going home.

The filler safety guide covers the risks of filler in general, and the dermal fillers page describes how treatment is planned here. A plan that recommends no filler under the eyes is a legitimate outcome of a careful consultation.